http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#Head http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#assertion http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#provenance http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#pubinfo http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#assertion http://purl.obolibrary.org/obo/DOID_8567 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_8567 http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00262 http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#association http://www.w3.org/2000/01/rdf-schema#label carmustine for injection usp is indicated as palliative therapy as a single agent or in established combination therapy in the following brain tumors glioblastoma brainstem glioma medulloblastoma astrocytoma ependymoma and metastatic brain tumors multiple myeloma in combination with prednisone relapsed or refractory hodgkin s lymphoma in combination with other approved drugs relapsed or refractory non hodgkin s lymphomas in combination with other approved drugs carmustine for injection usp is a nitrosourea indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following brain tumors glioblastoma brainstem glioma medulloblastoma astrocytoma ependymoma and metastatic brain tumors 1 multiple myeloma in combination with prednisone 1 relapsed or refractory hodgkin s lymphoma in combination with other approved drugs 1 relapsed or refractory non hodgkin s lymphomas in combination with other approved drugs 1 http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00262 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#provenance http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#pubinfo http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#sig http://purl.org/nanopub/x/hasSignature FF/pUWp+bo3IA0XV6oV5uPiP3kVLfWQ9GBsKPDYvwlFnlwJDcjp/eEHUOwpCHka6ndQkf3/coSgFUUg4YuUtV/ckYI3tXy1baggJB1yCjoGbzNWgRui71MpWYbkg0+x07ro/wzRGDnDtTpCt1I4ypM+wPDrRNjYuKZjeSlL3CGk= http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I http://purl.org/dc/terms/created 2021-06-28T08:06:40.117+02:00 http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RANhEw1pUj2Yb6RvsXCNb5UfH_E4ezgBbN87i2_DpyV3I https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs